Article Text

Download PDFPDF
SNIS 9th annual meeting oral poster abstracts
P-021 A randomized trial comparing platinum and hydrogel-coated coils in patients prone to recurrence after endovascular treatment—the PRET trial
  1. J Raymond,
  2. D Roy,
  3. A Weill
  1. Department of Radiology, CHUM Notre-Dame hospital, Montreal, QC, Canada


Purpose The PRET trial aims compares hydrocoils to bare platinum coils in patients with aneurysms prone to recurrence, that is, in patients with large aneurysms (≥10 mm; PRET-1 patients) or in patients with a major recurrence after previous coiling (PRET-2 patients). We aim at reporting an update of the randomization rate and results of the interim analysis from the DMSC.

Materials and Methods PRET is a RCT with single-blind allocation. 500 subjects are followed for 18 months. PRET-1 (250) and PRET-2 (250) cases are randomized separately. Interventions are : a/bare coil embolization, or b/hydrocoil embolization. Primary endpoint is recurrence rate. Secondary endpoints include procedural complications, clinical outcome, safety of hydrogel coiling and overall M&M.

Results 344 PRET subjects were randomized by 33 sites in Canada, US, France, UK, Japan and Chile. Baseline characteristics of the first 264 PRET subjects were (mean (SD)): Age = 59 (11) years; 73% had only one aneurysm; 16% presented with acute rupture of the aneurysm; Aneurysm parameters for PRET1 subjects (53%) were: size = 14 (5) mm and in 57% of cases located in the anterior circulation. Aneurysm parameters for PRET2 subjects (47%) were: size = 13 (11) mm and in 57% of cases located in the anterior circulation. An interim safety analyses carried out on 234 subjects did not reveal any significant difference in SAEs or clinical outcome (mRS>2 at discharge and 1-month follow-up) between treatment arms.

Conclusion We hope that PRET will show that for the treatment of aneurysms prone to recurrence, Hydrocoils provide an equal or higher efficacy than bare platinum coils with no difference in safety profile.

Competing interests J Raymond: Microvention Inc. (investigator-led clinical trial funding for PRET). D Roy: None. A Weill: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.